在因果关系评估中质疑潜伏期:关于阿托瓦斯塔丁的肝毒性
Alicia Ruiz Sánchez1, Marisa Ojeda Salvador1, José Manuel Sousa Martín1
1UGC de Aparato Digestivo, Hospital Universitario Virgen del Rocío.
Revista espanola de enfermedades digestivas
|June 12, 2025
概括
这项研究报告了一例罕见的阿托瓦斯塔丁诱导胆固醇性肝炎病例,发病时间显著延迟. 这些发现强调了考虑药物诱导的肝损伤的重要性,即使在长期暴露于降脂他类药物后也是如此.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
- 药物诱导的肝损伤
背景情况:
- 阿托瓦斯塔丁是一种用于管理高脂血症的广泛处方的他类药物.
- 包括阿托瓦斯塔丁在内的他类药物与潜在的肝毒性有关.
- 药物诱导性肝损伤的延迟发病不太常见,但有记录.
研究的目的:
- 呈现一种因阿托瓦斯塔丁而导致的胆固醇性肝炎病例.
- 为了突出阿托瓦斯塔丁肝毒性异常长的潜伏期.
- 讨论将肝损伤归因于延迟发作的药物所带来的诊断挑战.
主要方法:
- 案例报告的呈现方式.
- 审查患者的临床病史,实验室值和药物治疗史.
- 使用已建立的药物诱导肝损伤标准评估因果关系.
主要成果:
- 患者患上了胆固醇性肝炎.
- 肝损伤的发作发生在长期使用阿托瓦斯塔丁后.
- 尽管推迟了介绍,但确立了因果关系,挑战了典型的预期.
结论:
- 阿托瓦斯塔丁可以引起胆固醇性肝炎,延迟潜伏期.
- 长时间的潜伏期可能会使药物诱导的肝损伤的诊断复杂化.
- 临床医生应保持对药物诱导的肝损伤的高度怀疑指数,即使出现延迟症状.
更多相关视频
相关概念视频
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
584
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
584
Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
34
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
34
Drug Concentration Versus Time Correlation
663
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
663
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
110
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
110


